Detalhe da pesquisa
1.
Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/ß-catenin-driven hepatocellular carcinoma.
J Hepatol
; 72(1): 104-118, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31541681
2.
A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids.
NPJ Precis Oncol
; 8(1): 52, 2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38413740
3.
Splice-switch oligonucleotide-based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC-driven hepatocellular carcinoma.
Bioeng Transl Med
; 8(1): e10363, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36684069
4.
Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer.
Mol Oncol
; 17(11): 2275-2294, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36896891
5.
Artificial Intelligence Effecting a Paradigm Shift in Drug Development.
SLAS Technol
; 26(1): 3-15, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32940124
6.
Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma.
Exp Hematol Oncol
; 9: 8, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32477831
7.
Artificial Intelligence-Driven Designer Drug Combinations: From Drug Development to Personalized Medicine.
SLAS Technol
; 24(1): 124-125, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30249153
8.
Datasets describing the growth and molecular features of hepatocellular carcinoma patient-derived xenograft cells grown in a three-dimensional macroporous hydrogel.
Data Brief
; 18: 594-606, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29900213
9.
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Sci Transl Med
; 10(453)2018 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30089632